Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine-releasing intravesical system
- Development stage
- Phase 3
- Lead developer
- Janssen Biotech
- Modality
- Small Molecules
- Administration
- Intravesical
01
Overview
A controlled-release, drug-device combination product designed to deliver gemcitabine directly into the bladder over an extended period. The system consists of a small, flexible tube-like device with a solid core of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antitumor activity. After placement in the bladder, it provides sustained local release of gemcitabine for up to 7 days. The mechanism involves cellular uptake of gemcitabine via nucleoside transporters; intracellular phosphorylation produces active metabolites that inhibit DNA synthesis and ribonucleotide reductase, leading to apoptosis in cancer cells. Developed primarily for high-risk non-muscle invasive bladder cancer (NMIBC), especially in patients unresponsive to BCG therapy[1][2][3][4][5][6].
- Brand names
- GemRIS
- Other names
- gemcitabine-releasing intravesical systemTARIS (as in "Gemcitabine-releasing intravesical system - TARIS")
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on gemcitabine-releasing intravesical system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine-releasing intravesical system.